The pharmaceutical company PJSC “Kyiv Vitamin Plant” (KVP) increased its net profit 2.1-fold in 2025 compared to 2024, reaching UAH 328.461 million.
As reported by the company in the disclosure system of the National Securities and Stock Market Commission (NSSMC), net revenue from product sales for 2025 increased by 3.13%—to nearly UAH 5.099 billion.
As previously reported, the company planned to increase sales volumes by 17.5% by the end of 2025.
In 2024, KVZ increased its net profit by 8.74% compared to 2023—to UAH 156.84 million; revenue from product sales last year rose by 14.71%—to UAH 4.944 billion.
KVZ is among the top ten largest pharmaceutical companies in Ukraine. The company’s product portfolio includes over 100 medicinal products and 20 dietary supplements.
According to the Opendatabot system, the ultimate beneficiary of KVZ is Canadian citizen Maxim Martin.
